Novavax and the Changing Covid-19 Vaccine Game – InvestorPlace

The last time I looked at Novavax (NASDAQ:NVAX) stock, I concluded that finishing third in the Covid-19 vaccine race may be good enough.

Source: Ascannio/Shutterstock.com

It has been quite good for Novavax shareholders. The stock is up 120% in 2021. Thats less than half the gain of rivals BionTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA), but theyve both gotten Covid-19 vaccines approved and into production.

Novavax is still working on it.

Novavax isnt really third, either. Johnson & Johnson (NYSE:JNJ) has had its vaccine out for months. AstraZeneca (NYSE:AZN) has a vaccine. There have been five Chinese vaccines and lots more are on the way.

But Novavax has a cunning plan that could still make it a big winner.

The new game starts with the World Health Organization. It badly wants cheap, effective Covid-19 vaccines delivered around the world, yesterday.

Novavax filed for an emergency approval from WHO on its Covid-19 vaccine. This is an end-run around western agencies that have yet to approve it.

The best vaccines, in terms of efficacy, seem to be those based on messenger RNA (mRNA) technology. Novavax is a protein-based vaccine, along with an adjuvant meant to increase its effectiveness. But our Louis Navellier still thinks Novavax can be a winner in this race. Thats because Novavax compound doesnt require cold storage, like mRNA vaccines.

Novavax is working closely with groups like the Gavi vaccine alliance, which are focused on pooled procurement and equitable distribution. It has an agreement to produce its vaccine in India, and a manufacturing agreement in South Korea.

Manufacturing remains the big if. Novavax says it has production agreements for 2 billion shots next year. But so far, its only production is for clinical trials.

The good news is that if you got a Novavax vaccine in its U.S. trial, youre now considered fully vaccinated. The bad news is that Novavax is still in the process of applying for an emergency use authorization (EUA), which would open the U.S. market.

Novavax also has a flu vaccine in development, called NanoFlu. This failed in previous Phase 3 trials. But it seems to have succeeded in meeting primary endpoints in its latest trial.

This let Novavax begin work on a combined COVID-influenza vaccine, one that would be shelf stable and easily tolerated.

Novavax says its now up to policymakers, not corporations, to drive the use of vaccines. While it opposes a waiver on patents, Novavax work is aimed at making it the low price leader on safe, effective, combination vaccines for a global market.

If Novavax can manufacture its vaccine in quantity, its projecting 2022 revenue of $5.23 billion, with net income of $30.21 per share. That would make the current price of $232 look cheap. The stock would be trading at just 3.6x forward revenue and 8.5x forward earnings.

There remain big ifs around NVAX stock.

If it can scale production, and if it can get approval, and if it can combine its flu vaccine with the Covid-19, Novavax could be a home run for investors in 2022.

Novavax has been hiring experienced pharmaceutical executives, in hopes of getting across the finish line and proving its case to investors.

But there remain uncertainties in the Novavax story. The success of Pfizer (NYSE:PFE), Moderna and BionTech is certain. If youre buying NVAX stock today, youre speculating. At this point in the Covid-19 race thats the best route to fat profits. But its also the riskier play.

On the date of publication, Dana Blankenhorn held long positions in MRNA. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines.

Dana Blankenhorn has been a financial and technology journalist since 1978. He is the author of Living With Moores Law: Past, Present and Future available at the Amazon Kindle store. Write him at danablankenhorn@gmail.com or tweet him at @danablankenhorn. He writes a Substack newsletter, Facing the Future, which covers technology, markets, and politics.

Read more from the original source:

Novavax and the Changing Covid-19 Vaccine Game - InvestorPlace